#### Additional Information
Optimal planning when assuming a prior distribution for the treatment effect can be done withe the help of the R package drugdevelopR (available at: https://github.com/Sterniii3/drugdevelopR) for programs 
* in the basic setting (Kirchner et al., 2016), 
* with multiple phase III trials (Preussler et al., 2019a) or
* with bias adjustment (Preussler et al., 2019b)


#### References

Goette, H., Schueler, A., Kirchner, M., & Kieser, M. (2015). Sample size planning for phase II trials based on success probabilities for phase III. <i>Pharmaceutical Statistics</i>, 14(6), 515-524.

Kirchner, M., Kieser, M., Goette, H., & Schueler, A. (2016). Utility-based optimization of phase II/III programs. <i>Statistics in Medicine</i>, 35(2), 305-316.

Preussler, S., Kieser, M., and Kirchner, M. (2019a). Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed. <i>Biometrical Journal</i>, 61(2), 357-378.

Preussler, S., Kirchner, M., Goette, H. & Kieser, M. (2019b). Optimal designs for phase II/III drug development programs including methods for discounting of phase II results. Submitted to peer-review journal.

#### Maintainer

Stella Preussler, Institute of Medical Biometry and Informatics, University of Heidelberg, email: Preussler@imbi.uni-heidelberg.de.

Beta version 0.4

